Chembio Diagnostics Inc  

(Public, NASDAQ:CEMI)   Watch this stock  
Find more results for CEMI
6.78
+0.41 (6.44%)
Real-time:   1:20PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.38 - 6.80
52 week 3.33 - 9.40
Open 6.39
Vol / Avg. 54,990.00/43,463.00
Mkt cap 59.16M
P/E     -
Div/yield     -
EPS -0.21
Shares 9.67M
Beta 1.04
Inst. own 16%
Jul 25, 2016
Q2 2016 Chembio Diagnostics Inc Earnings Release
May 12, 2016
Q1 2016 Chembio Diagnostics Inc Earnings Call - Webcast
May 12, 2016
Q1 2016 Chembio Diagnostics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -4.60% -9.88%
Operating margin -7.09% -14.65%
EBITD margin - -8.99%
Return on average assets -5.94% -10.46%
Return on average equity -6.94% -12.82%
Employees 155 -
CDP Score - -

Address

3661 Horseblock Rd
MEDFORD, NY 11763-2215
United States - Map
+1-631-9241135 (Phone)
+1-775-8849383 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company's product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.

Officers and directors

John J. Sperzel III President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Richard J. Larkin Chief Financial Officer
Age: 58
Bio & Compensation  - Reuters
Sharon Klugewicz Chief Operating Officer
Age: 47
Bio & Compensation  - Reuters
Javan Esfandiari Chief Science and Technology Officer
Age: 48
Bio & Compensation  - Reuters
Tom Ippolito Vice President - Regulatory Affairs, Quality Assurance and Quality Control
Age: 52
Bio & Compensation  - Reuters
Paul Lambotte Ph.D. Vice President - Product Development
Age: 63
Bio & Compensation  - Reuters
Michael K. Steele Vice President - Business Development, Sales and Marketing
Age: 48
Bio & Compensation  - Reuters
Katherine L. Davis Non-Executive Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Peter T. Kissinger Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Gary Meller M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters